Molbio Diagnostics Eyes ₹940 Crore Through IPO for Expansion Plans

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is preparing for an initial public offering (IPO) to raise ₹940 crore. The company plans to secure ₹200 crore through a fresh issue of shares dedicated to capital expenditures. Simultaneously, it seeks to gather ₹740 crore via an offer for sale, which will reduce the promoter group's stake from 46.6% to 43%.

Global Reach and Product Portfolio

Founded in 2000, Molbio Diagnostics operates six manufacturing facilities across India, serving clients in over 90 countries. The company has established a strong foothold in the diagnostics industry through its innovative solutions for both infectious and non-communicable diseases. The 'Truenat' platform, a portable diagnostics system, is one of its flagship products, offering rapid and accurate test results, particularly valuable in resource-limited settings.

Molbio's diverse offerings include molecular testing solutions for over 30 diseases, with a significant focus on tuberculosis diagnostic test kits. These kits account for a substantial portion of the company's revenue, which is largely driven by government health programs and international aid agencies.

Strong Financial Performance

Between FY24 and FY26, Molbio Diagnostics reported a 31.5% annual increase in revenue from operations, reaching ₹1,445.7 crore. During the same period, net profits surged by 40.2% to ₹164.1 crore. The company's EBITDA also grew by 33.2%, amounting to ₹328.2 crore, with margins improving from 22% to 22.6%.

The fiscal year 2026 alone saw a 41.7% rise in revenue, a 27.9% increase in EBITDA, and an 18.4% growth in net profit year-on-year. These figures highlight Molbio's robust financial health, positioning it as a promising investment opportunity despite the inherent risks associated with IPOs.

Valuation and Market Position

Molbio Diagnostics is seeking a price-earnings (P/E) multiple of up to 57 post-IPO, a competitive valuation in comparison to other healthcare diagnostics and medical device firms such as Poly Medicure, Dr. Lal PathLabs, and Metropolis Healthcare. These peers currently trade at P/E multiples ranging from 54 to 81.

With no directly comparable listed peers in India, Molbio's IPO presents a unique opportunity for high-risk investors looking for growth in the dynamic diagnostics sector. The company's strategic focus on expanding its product portfolio and enhancing production capabilities through fresh capital could pave the way for sustained long-term growth.